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Title: The Effects of Pulmonary Hypertension in Diabetic Zucker Rats on Pulmonary
Vascular Contraction and Right Ventricular Size.
Literature Review
Introduction
Pulmonary hypertension is a life-threatening disease that is identified by a resting
mean pulmonary arterial pressure over 25 mmHg and established by right heart
catheterization (Saglam et al., 2015). The symptoms commonly associated with
pulmonary hypertension include fatigue, dyspnea, syncope, and chest pain, which
severely limit quality of life in diagnosed patients (Saglam et al., 2015). According to
recent studies in patients with pulmonary hypertension, the one, three and five year
mortality rates are 8%, 25%, and 34%, respectively (Burudpakdee, Shah, Joish, Divers, &
Yaldo, 2014). Although some advances have been made in therapies for pulmonary
hypertension, the prognosis is still poor, and there is a lack of understanding of its
mechanisms (Voelkel, Gomez-Arroyo, Abbate, Bogaard, & Nicolls, 2012). This study
aims to examine and understand some of those mechanisms in the Zucker Rat.
Additionally, previous analyses have shown that individuals with diabetes
mellitus have an increased incidence of pulmonary hypertension (Gurney, & Howarth,
2009). The number of individuals with diabetes has skyrocketed in previous years, and
the International Diabetes Federation shows that the worldwide prevalence of diabetes as
of 2013 is 382 million (Shi, & Hu, 2014). Additionally, this number is expected to rise
and could be as high as 592 million by 2035 (Shi, & Hu, 2014). Dynamics that could
bring about pulmonary hypertension associated with diabetes include microvascular
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disease, autonomic neuropathy, and metabolic derangements such as hyperglycemia and
dyslipidemia (Blendea, McFarlane, Isenovic, Gick, & Sowers, 2003). The mechanisms of
these dynamics are poorly understood, and the relationship between pulmonary
hypertension and diabetes should be examined. The purpose of this study was to examine
the difference in effect of diabetes on pulmonary hypertension using an animal model.
Pulmonary Hypertension
Pulmonary hypertension (PH) is a dynamic disease distinguished by the
uncontrolled growth of smooth muscle and pulmonary vascular endothelial cells causing
constriction of the pulmonary arteries which results in abnormally high vascular
resistance and failure of the right heart characterized by right ventricular hypertrophy
(Moral-Sanz et al., 2011). Right ventricular hypertrophy eventually causes heart cells to
die, which has been demonstrated to be a crucial event during the end stages of heart
failure (Doggrell, & Brown, 1998). A number of possible causes of PH have been
identified, but the mechanisms of the disease are complicated and poorly understood
(Brunner et al., 2014). Although progress has been made in the management of PH, the
prognosis is still poor, and there is currently no curative treatment for this destructive
disease (West et al., 2014; Farkas, & Kolb, 2013). Current vasodilator treatments act to
increase circulation in the lungs and help to stave off increased pulmonary vascular
pressures resulting in right ventricular hypertrophy. However, this does not target the
underlying problem of the disease, which is pulmonary vascular remodeling (Farkas, &
Kolb, 2013).
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Diabetes Mellitus Type II
Diabetes is a disease chiefly distinguished by high blood sugar levels that increase
the risk of developing microvascular damage such as retinopathy, neuropathy, and
nephropathy. According to the World Health Organization, it decreases life expectancy
and shows appreciable morbidity due to diabetes related microvascular problems, a lesser
quality of life, and serious macrovascular problems such as heart disease, peripheral
vascular disease, and stroke. Diagnosis of diabetes has seen a startling increase in the past
twenty years, and current statistics show approximately 6.4% of the world’s population
has some form of diabetes (Carter, Gray, Troughton, Khunti, & Davies, 2010).
According to Movahed and colleagues (2005), the prevalence of PH in diabetic
patients is significantly higher independent of other comorbidities such as coronary artery
disease, hypertension, heart failure, or smoking. One of the complications of uncontrolled
glucose levels in diabetes is the development of pulmonary hypertension (Gurney, &
Howarth, 2009). Recent studies have also linked endothelial dysfunction as an important
factor in the progression of diabetic retinopathy, nephropathy, and atherosclerosis in both
types of diabetes (Lopez-Lopez et al., 2008). Despite the close relationship with systemic
and pulmonary cardiovascular disease, it has only been shown recently that type 1 and
type 2 diabetes are risk factors for pulmonary hypertension. Limited research has been
conducted to examine this relationship (Lopez-Lopez et al., 2008).
Pharmacology
Potassium Chloride (KCl). Potassium chloride (KCl) has been used in a number
of studies to produce substantial contractions in mammalian cardiac muscle. It has also
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been used to avoid G-protein coupled receptor (GPCR) activation and mobilize smooth
muscle by altering the K+ equilibrium potential and fastening membrane potential above
the resting level. It has been used in other studies to induce maximum contractions in
vascular smooth muscle that can then be used as a reference for further experimentation
(Schuh et al., 2003). Because of these substantial contractions, KCl was used in the study
to test pulmonary arterial vascular rings for contractility (Bassett, & Wiggins, 1976).
Phenylephrine. Phenylephrine is a sympathomimetic vasoconstrictor similar in
structure to epinephrine. Its chemical structure deviates from epinephrine only in the
absence of one hydroxyl group on the benzene ring (Eccles, 2007). Phenylephrine is a
somewhat discriminatory α1 agonist, with poor α2 agonist activity (Eccles, 2007). It
induces contraction of muscle through various mechanisms and calcium channels such as
L-type voltage-operated calcium channels and receptor-operated calcium channels (Kim,
et al., 2014). Phenylephrine was used in this study to initiate pulmonary arterial vascular
contraction.
Acetylcholine Acetylcholine is a neurotransmitter that plays an important role in
many biological processes of both the central and peripheral nervous system (Pinheiro et
al., 2015). The synthesis of acetylcholine occurs in an uncomplicated biochemical
process. It involves the transfer of the acetyl group from acetyl-coenzyme A to choline by
an enzyme called choline acetyltransferase (Schwarz et al., 2013). Once synthesized,
acetylcholine is the excitatory neurotransmitter used at the synapse between the
neuromuscular junctions in mammals (Bagnall, du Lac, & Mauk, 2013). It has also been
documented to induce smooth muscle dilation in vivo in mammalian pulmonary arteries
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and systemic arteries and was used in this study to induce vasodilation of pulmonary
arterial vasculature (Vanhoutte, Rubanyi, Miller, & Houston, 1986)
Monocrotaline (C16H23NO6). Monocrotaline (MCT) is a toxic pyrrolizidine
alkaloid derived from the seeds of the Crotalaria spectabillis plant. When administered
in small doses caused delayed and progressive lung injury resulting in pulmonary
vascular remodeling, pulmonary hypertension and resultant right heart hypertrophy
(Schultze & Roth, 1998; Broderick, Wang, Gutkowska, Wang, & Jankowski, 2010).
Pulmonary hypertension produced by MCT injection is well documented in numerous
rodent studies of pulmonary hypertension (Broderick, T. L., & King, T. M. 2008).
Animal Models
The utilization of the rat animal model is economically reasonable and allows for
measurement of important hemodynamic and cardiac parameters in vitro (Doggrell, &
Brown, 1998). The Obese Zucker rat has been used in many studies and has become a
popular model for type II diabetes and its links to systemic vascular dysfunction (MoralSanz, Moreno, Cogolludo, & Perez-Vizcaino, 2014). These Zucker rats typically develop
obesity and insulin resistance around seven weeks of age (Schmidt, Dorsey, Beaudet, &
Peterson, 2003; Shiota, & Printz, 2012).
This study examined a variety of factors including right ventricular pressures and
heart weights, right ventricular ratios, and contractility properties of the pulmonary
vascular ring using a Schuler tissue bath. Elevation of right ventricular pressures and the
development of right ventricular hypertrophy are clinical signs of pulmonary
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hypertension resulting in pulmonary arterial vascular remodeling with thickening of the
vascular wall which may impact contractile and/or relaxant ability of the vessel.
Specific Aims
The aims of this study are to compare the effects of pulmonary hypertension
between non-diabetic control Zucker rats and Zucker rats with PH and PH plus Type II
diabetes in terms of pulmonary artery relaxation function and right ventricular
hypertrophy.
Hypothesis
The hypotheses of this study are
1. The pulmonary arterial vascular contractile responses will be decreased in the PH
and PH plus type II diabetic rats as compared to the control rats; and
2. The pulmonary arterial vascular relaxant responses will be decreased in the PH
and PH plus type II diabetic rats as compared to the control rats.
Methodology
This study was performed following approval of University of Arkansas-Fayetteville
Institutional Animal Care and Use Committee (IACUC). All University and Laboratory
Animal Training Association (LATA) protocols and guidelines for animal handling were
followed.
Sample
An a priori power analysis was conducted to establish group sizes of 8 were
sufficient to achieve a power value of >.80. A three-group experimental design was used.
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The groups consisted of age-matched Zucker rats including 9 control Zucker rats, 6 lean
PH Zucker (Fa/fa) rats and 4 type II diabetic PH Zucker (fa/fa) rats(Harlan Laboratories,
Indianapolis, IN). The study experienced a 50% death rate (n=4) in the lean Zucker
(Fa/fa) rats and 1 death in the type II diabetic Zucker (fa/fa) group prior to the
experiment. Additionally the study experienced 1 type II diabetic Zucker (fa/fa)
pulmonary artery tissue death during the experiment accounting for the variable number
of rats in each group.
Animal Care
Animals were received into the Central Live Animal Facility (CLAF) facility and
allowed to acclimate to their surroundings for two weeks. Animals were housed two rats
per cage (10.25”W X 19”D X 8”H) with micro-filter tops and autoclaved pine litter. The
animals were allowed standard rat chow food and water ad libitum. A reversed 12:12
light-dark cycle was used and the rats were allowed unrestricted cage activity. All
procedures were performed under a laminar hood in the CLAF facility until the terminal
phase of the experiment. At that time, animals were transported to Dr. Smith-Blair’s
laboratory in HHPR 321 and allowed to acclimate for a minimum of 1 hour prior to the
beginning of the experiment.
Pre-Experiment Protocol
Monocrotaline (MCT) Injection Procedure Following the arrival and a two
week stabilization period in the CLAF, MCT 40 mg/kg was injected subcutaneously into
the experimental groups of rats. This dose of MCT has been demonstrated by Handoko
and colleagues (2009) to produce stable pulmonary hypertension with a preserved cardiac
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output. The animals were observed daily for four weeks for clinical signs of complicating
right heart failure and compromised cardiac output (respiratory distress, cyanosis,
lethargy, weight loss, and decrease in responsiveness to stimulation). Five animals were
euthanized according to the approved IACUC protocol due to progressive pulmonary
decompensation with persistent weight loss and lethargy.
Body Weight/Blood Glucose Body weight was measured daily and blood
glucose levels measured weekly on all animals. Blood glucose levels were obtained using
a micro-lancet to obtain blood from the rat tail and measured using the Accu-Check
Active™ meter.
General Experimental Procedures
On the day of the terminal phase of the experiment, the animals were transported
to the laboratory and allowed to acclimate for a minimum of 1 hour. Following obtaining
a surgical plan of anesthesia using pentobarbital sodium (50 mg/kg body weight), a
tracheotomy was performed and a stainless steel tracheotomy cannula with Luer adapter,
1.8 mm OD, 25 mm in length (Harvard Apparatus, Holliston, MA) was inserted and
sutured in place. The tracheal cannula was connected to pressure-controlled rat ventilator.
The settings of the rodent ventilator were 10 mL/kg (tidal volume) and 60 cycles/min.
The diaphragm was exposed via a midline abdominal incision. A 20G needle
attached to a low pressure transducer was inserted through the diaphragm into the right
ventricle. Right ventricular pressure was measured via the Digi-Med™ (Model 200) lowpressure transducer. This model of transducer measures pressures within an error range of
+ 0.1 mmHg.
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Following obtaining the right ventricular pressure, the animal was given an
overdose of pentobarbital (100 mg/kg body weight). The thorax was quickly opened
surgically and the heart and lungs removed. The heart and lungs were submerged in a
dissection dish containing Krebs solution bubbled with low flow 95% oxygen/5% CO2.
Vascular Reactivity Studies The pulmonary artery rings (~2 mm long and an
internal diameter ~ 0.3-0.5 mm) were dissected and mounted on a tissue hook supports in
a Schuler tissue bath™ (Harvard Apparatus, Holliston, MA). After stretching to give an
appropriate resting tension (equivalent to 0.75 g), tissues were continuously bathed in the
chamber with Krebs solution at 37⁰C with a mixture of 95% O2-5% CO2 as previously
described by Cogollundo et al (2001).
KCL contraction challenge. Following equilibration, the vascular muscle
contractile responses were evaluated using a KCL 96mM solution infused into the tissue
bath chamber. This procedure was performed to obtain a baseline measurement of the
viability of each pulmonary artery vessel to ensure the artery was not damaged during
isolation or mounting of the vessel. The KCL was allowed to saturate the vascular ring
for 2 minutes after which the peak contraction was recorded. Following measurement, the
vessel was thoroughly rinsed with Krebs’ solution and the vascular ring allowed for
equilibrate for 10 minutes. This process was repeated twice. Following the experiment
the developed force was calculated (peak contractile force – resting tension) to reflect the
change in contractile properties of the vessel.
Tissue rings were then exposed to phenylephrine 10-9 to 10-4 mM concentrations
to induce a contraction 70% of the KCl max contraction is obtained. Tissues were rinsed
thoroughly between concentration level testing and allowed to rest 2 minutes. Once the
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phenylephrine concentration producing 70% of the response to KCl, Phenylephrine (10-7
mM) was used to evaluate the contractile response.
The tissue baths were then infused with phenylephrine (10-7 mM) along with
increasing concentrations of acetylcholine (10-9to 10-4 mM) to test the relaxant properties
of the tissue. Concentration curves were obtained for acetylcholine concentrations (10-9to
10-4 mM).
Measurements obtained in this study included the following: baseline resting
tension, peak contraction, and developed force (calculated). The optimal baseline resting
tension was determined prior to the start of each experiment and was adjusted to be
maintained constant throughout the experiment. The peak contraction was determined as
the maximum force (gms) produced by the pulmonary arterial vascular ring when
exposed to either KCL, phenylephrine or phenylephrine/acetylcholine solutions. The
developed force was calculated as difference between the peak contraction and the
baseline resting tension and was used as the measure of contractile change with each
measurement. Using these measurements, the effectiveness of the various concentrations
of phenylephrine and phenylephrine/acetylcholine was gauged.
Results
A one-way analysis of variance (ANOVA) was used to examine if there were
statistically significant differences between the means of the three groups in relation to
weight, height, blood glucose, KCl contractions, and heart weight and heart ratio. Second,
one-way repeated measures ANOVA was used to examine if differences existed between
groups with respect to developed force at varying concentrations of phenylephrine and
phenylephrine/acetylcholine solutions.
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An initial alpha level of 0.05 was selected as the criterion for statistical
significance. This level of significance was then adjusted to an alpha level of 0.01 using
an adjustment in the Bonferroni procedure to control for an overall type I error rate due to
performing multiple analyses. To account for deviations from sphericity, the GreenhouseGeisser Epsilon correction factor was used to adjust the univariate test degrees of
freedom for each test involving with-in subject effects.
Weight and Length. Three groups of rats, two groups with induced pulmonary
hypertension (PH) and one control group, were used for these experiments and included
control lean rats (N=9), lean PH rats (N=6) and type II diabetic PH rats (N=4). An
ANOVA demonstrated there was a statistically significant difference between groups
with respect to weight [F (2, 18) = 87.25, p < .005]. Post hoc tests revealed there was a
statistically significant difference between the diabetic PH rats and the lean control rats
(p< .005) and lean PH rats (p < .005) but there was not a statistically significant
difference in weight between the lean PH and lean control rats (Figure 1). An ANOVA
did not reveal a significant difference in body length measurements between the groups
(Figure 2)
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*

**

Figure 1 – Comparison of mean weights (gms) between lean PH, Diabetic PH and control
rats. No statistically significant difference was noted between Lean PH and Control rats.
*Denotes a significant difference between Lean PH and Diabetic PH rats.
**Denotes a significant difference between Diabetic PH rats and Control rats.
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Figure 2 – Comparison of the body lengths (cm) of the three groups. No statistically
significant differences were noted between groups in relation to length

Blood Glucose Levels. Blood glucose levels were monitored weekly and
analyzed using ANOVA. A statistically significant difference in blood glucose was noted
between groups [F (2, 18) = 243.94, p < .005]. A post hoc test revealed a statistically
significant higher blood glucose levels in the diabetic PH than the lean PH rats (p< .005)
and lean control rats (p <.005). There was not a statistically significant difference in
blood glucose levels between the lean PH and lean control rats (Figure 3).
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*

*

Figure 3 – Comparison of the mean blood glucose levels (mg/dL) of the three groups.
* Denotes statistically significant difference between Lean PH rats and Diabetic PH rats
and between Diabetic PH rats and Control rats. No statistically significant difference in
blood glucose between Lean PH and Control rats.

Right Mean Ventricular Pressures. An ANOVA revealed a statistically
significant difference in the mean right ventricular pressures between the three groups [F
(2,18) = 14.46, p < .005]. Post hoc tests revealed there was not a statistically significant
difference between the right mean ventricular pressures in the lean PH and diabetic PH
rats. However, the control rats had statistically significant lower right ventricular
pressures than either the lean PH rats (p= .001) or the diabetic PH rat (p=.002) (Figure 4).
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*

Figure 4 – Mean right ventricular pressures between the three groups
* Denotes statistically significant difference in right ventricular pressure between Lean
PH and Diabetic PH with regard to Control rats.

Mean Heart Weight. An ANOVA determined there was a statistically significant
difference between the three groups with regard to mean heart weight [F (2, 18) =16.86,
p<.005]. Post hoc comparisons indicated a statistically significant increase in the lean PH
(p=.001) and diabetic PH (p<.005) rate mean heart weights as compared to the control rat
mean heart weights (Figure 5).
Heart weight Ratio. Heart weight ratios were calculated by the following
formula: (left ventricular heart weight – septum)/right ventricular weight. An ANOVA
was used to determine if there were statistically significant difference between the three
groups of rats. The analysis did not demonstrate a statistically significant difference
between the groups of rats [F (2, 18) = .34, p= .71].
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*

Figure 5 – Mean Heart Weight comparisons between the three groups.
*Denotes a statistically significant difference between Lean PH and Diabetic PH with
regard to Control rats.

Potassium Chloride Infusion. Potassium chloride (KCl) infusions (0.096 mol/L)
were used to test the contractility of the pulmonary vascular arterial rings for viability. It
also was used to determine the concentration of Phenylephrine HCl infusion (a
concentration that produced 70% peak contraction generated by the KCl test) to be used
for the experiment. An ANOVA determined there was no statistically significant
difference in peak contraction between the groups with the first contraction test [F (2, 17)
= 1.96, p= .18] or the second contraction test [F (2, 17) = 3.28, p= .06] (Figure 6).
Additionally there was not statistically significant difference in developed force between
the groups [F (2, 14) = .63, p= .55].
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Figure 6 – Mean Peak Contraction (gms) with infusion of KCL. No statistically
significant difference was noted between groups with either KCl test.

Phenylephrine HCl Infusion. Following the KCl contraction tests, the
magnitude of developed force produced to achieve 70% of the peak KCl contraction
through stimulation of the pulmonary artery vascular ring was determined through
exposure of the tissues to phenylephrine HCl concentrations of -9 mOm to -4mOm
successively added to the tissue wells. A concentration of phenylephrine HCl -7mOm
was used as the constant infusate for the acetylcholine phase of the experiment based on
the peak contractions of the 3 groups (Figure 7).
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Figure 7 – Mean peak contraction at varying levels of phenylephrine
A one-way repeated measures ANOVA was used to determine if there was a
statistically significant difference in developed force at phenylephrine concentrations of 9 mOm, -8 mOm, and -7 mOm between the Control group, and the Lean PH and Diabetic
PH groups. The assumption of sphericity was not met, as assessed by Mauchly’s test of
sphericity, x2 (2) = 8.92, p= .01. Epsilon (Ɛ) was .61 as calculated by Greenhouse &
Geisser (1959), and was used to correct the one-way repeated measures ANOVA. The
change in phenylephrine concentrations did not elicit statistically significant changes in
developed force over time [F (1.23, 12.28) = 2.93, p = .12] (Figure 8).
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Figure 8. Developed force of pulmonary arterial vascular contraction (gms) at varying
levels of Phenylephrine

Acetylcholine/phenylephrine (-7mOm) infusion. Phenylephrine HCl
concentration (-7mOm) produced a peak contraction of 70% of the maximum contraction
obtained with the KCL infusion was infused in the tissue bath in combination with
acetylcholine concentrations from -9mOm to -4mOm. Following each successive
concentration of acetylcholine pulmonary arterial vascular contractility measures were
obtained. An ANOVA was used to determine if there were statistically significant
differences between the Control group, and the Lean PH and Diabetic PH groups at the
tested concentrations of phenylephrine/acetylcholine -9 mOm to -4 mOm. Mauchly’s test
of sphericity indicated that the assumption of sphericity had been violated, x2 (9) = 38.57,
p< .005. Therefore the Greenhouse & Geisser (1959) was calculated and used to correct
the one-way repeated measures ANOVA. There was no statistically significant
difference in peak contraction [F (2.22, 33.31) = 2.32, p= .11] or developed force [F
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(1.68, 25.14) = 2.17, p= .14] of the pulmonary arterial vascular tissue between any
concentrations of acetylcholine (Figure 9).

Figure 9. Acetylcholine/Phenylephrine Mean Peak Concentration between groups at
varying concentrations of acetylcholine. No statistical significant difference noted.
A one-way repeated measures ANOVA was computed to compare the developed
force by groups. Data from the acetylcholine/phenylephrine -5mOm concentration was
deleted from the observations due to an outlier. Mauchly’s test of sphericity indicated that
the assumption of sphericity had been violated, x2 (9) = 33.96, p< .005. Epsilon (ɛ) was
.415 as calculated by the Greenhouse & Geisser (1959), which was used to correct the
one-way repeated measures ANOVA. There was no statistically significant difference in
developed force [F (1.66, 21.59) = .964, p= .12] of the pulmonary arterial vascular tissue
between any concentrations of phenylephrine/acetylcholine (Figure 10).
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Figure 10 – Comparison of the Acetylcholine/Phenylephrine (-7mOm) Mean Developed
Force (gms) between the three groups. No statistically significant differences were noted
between groups at any of the acetylcholine concentrations.
Discussion
The body weights and lengths of the diabetic PH rats in our study were
significantly heavier than both the Lean PH and Control rats, which is consistent with the
literature (Moral-Sanz, et al., 2014). Additionally blood glucose levels of type II diabetic
Zucker rats were significantly higher (mean = 189.25 mg/dl) than the lean rats (mean =
87.0) or the control rats (mean = 87.0) confirming the development of type II diabetes.
This development which is consistent with insulin resistance in the Zucker rats (fa/fa) is
consistent with other studies (Schmidt, Dorsey, Beaudet, & Peterson, 2003).
Pulmonary hypertension is characterized by elevated pulmonary pressures
resulting in compensatory right ventricular hypertrophy. The weight of the right ventricle
can be used as an indirect index of pulmonary artery pressure. Increased right ventricular
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weight compared to the left ventricle plus the septum weight has been described in the
literature as a measure of the hypertrophy (Moral-Sanz et al., 2012). Additionally,
increased right ventricular pressure has also been noted in PH (Csiszar et al., 2009).
Statistically significant increases in right ventricular pressures seen in the lean PH and
diabetic PH rats were also consistent with the literature. Our data highlights the drastic
differences between the two experimental groups and the control group. Heart weights
and the heart weight ratio were determined in all animals to evaluate right ventricular
hypertrophy. The heart weights indicated that both experimental groups of rats had
greater heart weights than the control rats suggesting that pulmonary hypertension existed
in these groups. Hearts from rats affected with PH were hypothesized heavier than rats
that do not have PH which was consistent with the literature (Moral-Sanz et al., 2012).
However, we did not find an increase in heart weight ratio (left ventricular heart weight –
septum/right ventricular weight) in the PH experimental groups which came as a surprise
after significance was found in right ventricular pressures and heart weights. Although
measures to maintain reproducibility of heart dissection was observed by having the same
researcher dissecting each heart, some variation in tissue landmarks may have impacted
this latter measurement.
Potassium chloride was used to establish a maximum contraction of the tissues,
confirmed viability of the tissue samples, and provided a consistent level of contraction to
be achieved with the phenylephrine infusion. Although not statistically significant, it is
interesting to note that the diabetic PH group had a slightly higher mean peak contraction
in response to KCL infusion. The findings of the phenylephrine contractions correspond
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to results found in other studies that used similar concentration-response curves for
phenylephrine (Gomart et al., 2014).
It has been noted in numerous studies (Dietrich et al., 2010; Vanhoutte, Rubanyi,
Miller, & Houston, 1986) that acetylcholine induces smooth muscle dilation in
pulmonary arteries. We observed dose-related dilation effects and were able to compare
the differences between lean PH rats, diabetic PH rats, and a control group with neither
morbidity. The results of the study indicate that there were no significant differences in
the pulmonary artery contractile function between the three groups of rats. Additionally,
we found no statistically significant changes to the relaxant properties with increased
concentrations of acetylcholine. Although no significance was found in pulmonary artery
contractile function in this study, there may be alternative mechanisms that could be
tested instead of the dilation effects of acetylcholine. One such mechanism could be the
vasodilatory effects of nitric oxide (NO) on pulmonary artery contractile function
(Hampl, Tristani-Firouzi, Hutsell, & Archer, 1996). Future studies should aim to test
these alternative mechanisms.
The identified limitations encountered during the course of the research may have
impacted the results of the study. The laboratory experienced death of a large number of
obese Zucker rats. Additionally, we experienced death of one of the tissues after
extraction. Both factors limited the amount of data available to four rats in that group.
Possible causes of death for the rats may have included complications from the MCT
injection and the increase in severity of PH progressing to death in the animal. Although
the dosage of MCT used (40 mg/kg) has been found to produce stable PH in other studies
(Handoko et al., 2009) it is unclear why some animals experience a more severe disease
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progression. The total experimental time of these experiments was longer than other
studies, which include some ending as soon as 28 days post injection of MCT
(Dumitrascu et al., 2008). Our longer study period could have contributed to the higher
mortality from PH complications. Alternatively, a virus may have infected the rats and
been spread through their respiratory tract, although preventive measures were taken with
the micro-filter tops and autoclaved pine litter. The quick nature in loss of the animals
lends to an infection. In future research, extra measures should be taken to ensure that
fewer rat deaths are recorded.
Another limitation is that we induced pulmonary hypertension artificially through
MCT injection, and this is not the way it develops in vivo. The development of
pulmonary hypertension in vivo could create significant deviations from the results found
through artificially mimicking it with injection of MCT. Induction of pulmonary
hypertension with MCT happens in a matter of weeks, whereas development in vivo
takes much longer. During the experimental phase of the study, some variation in the
tissue extraction may have taken place. However, this limitation was addressed during the
experiments by having the same researcher extract all hearts for consistency. Although
the pH of the all solutions was carefully measured prior to injection into the tissue bath,
some change in pH may have occurred during the measurement phases of the experiment
which could affect the viability of the arteries. Both alkalosis and acidosis have a critical
influence on pulmonary artery viability.
A final limitation of the study may be the size of the isolated arteries used in the
study. The targeted tissues for dissection were the first branch of the right and left branch
of the pulmonary artery. Large conducting arteries contribute little to pulmonary vascular
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resistance. Resistance arteries are technically difficult to isolate and some degree of error
may have occurred with the dissection process of these arteries.
Future studies should aim to mimic a slower progression of PH such as hypoxia
and determine if there are ways to conduct a study similar to this on older rats since the
rats used in our study were young. The age of the animal can influence vascular function.
Aging is associated with structural changes and functional response of arteries. In
addition, it may help to extend the time each tissue is exposed to the dosages of KCl,
phenylephrine, and acetylcholine. When measuring the baseline for the tissues during
experimentation, ten minute time intervals were allowed between each dose of the three
chemicals for equilibration. Additional time may impact the measurements.
In summary, we have shown that there were no significant differences in the
pulmonary artery contractile function between the three groups. Additionally, pulmonary
arterial vascular relaxant responses were not significantly decreased in the PH and PH
plus type II diabetic rats compared to the control rats as hypothesized.
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